Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

February 16, 2021February 16, 2021

UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio

cystic fibrosis, News

The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K. clinical trial investigating ways of safely lowering the ... Read more

February 5, 2021February 5, 2021

Vitamin D in High Daily Doses Doesn’t Appear to Help – or Do Harm

cystic fibrosis, News

Higher doses of vitamin D supplements do not appear to lead to better clinical outcomes, either in lung function or bone health, in people with cystic fibrosis (CF), a systematic ... Read more

February 2, 2021February 2, 2021

CF Children May Take Enzyme Therapies on Own at Atlanta Hospital

cystic fibrosis, News

Hospitalized children and adolescents with cystic fibrosis (CF) who can take enzyme treatments for pancreatic insufficiency on their own, rather than waiting for them to be given by a nurse, ... Read more

January 18, 2021January 18, 2021

Bacteria in Irish Soil Seen to Block Those Tied to Chronic Lung Infections

cystic fibrosis, News

A species of antibiotic-producing bacteria able to inhibit the growth of antibiotic-resistant bacteria linked to chronic lung infections — found in the soils of Northern Ireland and long used in ... Read more

January 14, 2021January 14, 2021

UK Rare Diseases Framework Opens to Improve Diagnosis, Access to Care

cystic fibrosis, News

U.K. Rare Diseases Framework, a government-led approach to raising national awareness of rare disorders, accelerating diagnoses, and improving patient care and treatment, is now in practice. This framework, signed by ... Read more

January 7, 2021January 7, 2021

Inhaled-IV Antibiotic Combo May Better Treat Acute Flares Than IV-only Mix

cystic fibrosis, News

When given alongside the antibiotic Colistin (colistimethate), Cayston (aztreonam lysine), an inhaled antibiotic specifically targeting Pseudomonas aeruginosa, was superior to standard intravenous antibiotics at improving lung function and life quality among ... Read more

January 4, 2021January 4, 2021

Arcturus to Develop ARCT-032 as RNA Therapy for CF

cystic fibrosis, News

Arcturus Therapeutics has selected ARCT-032, an aerosolized RNA-based therapy, to be developed as a novel therapeutic candidate for cystic fibrosis (CF). The therapy will use the company’s LUNAR delivery technology ... Read more

December 22, 2020December 22, 2020

Antibiotic Gentamicin Can Be Effective Without Causing Deafness, Study Finds

cystic fibrosis, News

Scientists discovered the subtypes of gentamicin — a broad-spectrum antibiotic often used to treat bacterial infections in people with cystic fibrosis (CF) — that are more likely to cause deafness, ... Read more

December 18, 2020December 18, 2020

CF Trust Partners With CF Foundation to Develop Gene-editing Therapies

cystic fibrosis, News

The U.K. Cystic Fibrosis Trust is partnering with the U.S. Cystic Fibrosis Foundation to fund a Strategic Research Centre (SRC) — a virtual collaboration bringing together investigators with different backgrounds ... Read more

December 1, 2020December 1, 2020

Symkevi-Kalydeco Combo Approved in Europe to Treat CF Patients Ages 6–11

cystic fibrosis, News

The European Commission has approved the combination of Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor) for the treatment of children, ages 6 to 11, with cystic fibrosis (CF) carrying certain genetic mutations. ... Read more